PSA screening for prostate cancer should involve consideration of benefits and risks. Screening is associated with a small reduction in prostate cancer deaths; risks include overdiagnosis and unnecessary biopsy and treatment.
No takes yet. Share an insight, caveat, or question.
Pinsky et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: